{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-200476","form_type":"8-K","ticker":"TXMD","cik":"0000025743","company_name":"TherapeuticsMD, Inc.","filed_at":"2022-07-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:57.718923+00:00","generated_at":"2026-06-24T09:20:00.231591+00:00","sec_items":["1.01","8.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"TherapeuticsMD extends loan maturity to July 27, appoints CRO, explores Chapter 11","bullets":["Amendment No. 13 extends Financing Agreement maturity to July 27, 2022.","Company pays Lenders $2.9 million interest payment as part of amendment.","Jeffrey Varsalone of G2 Capital Advisors appointed as Chief Restructuring Officer.","Board evaluating all options including refinancing, strategic alternatives, and Chapter 11.","Company intends to maintain normal operations while evaluating options."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-200476","json":"https://secwatch.observer/filing/0001193125-22-200476.json","markdown":"https://secwatch.observer/filing/0001193125-22-200476.md","text":"https://secwatch.observer/filing/0001193125-22-200476.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/25743/000119312522200476/0001193125-22-200476-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/25743/000119312522200476/d387303d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T09:20:00.231591+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}